^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gocatamig (MK-6070)

    i
    Associations
    News

    Trials

    Company:
    Daiichi Sankyo, Merck (MSD)
    Drug class:
    CD3 agonist, DLL3 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727)
    Phase 1/2
    Harpoon Therapeutics, Inc., a subsidiary of Mer...
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/14/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)